	Adjuvant therapy for renal cell carcinoma An update to the Canadian Kidney Cancer Forum consensus statement. Can Urol Assoc J Lalani AA, Lavallée LT. PMID: 42900894 [PubMed]
	Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer. JCO Clin Cancer Inform Castro-Labrador L, Zamora R, Szyldergemajn S, Gómez Del Campo P, Del Castillo Izquierdo J, De All JA, Domínguez JM, Galmarini CM. PMID: 42900858 [PubMed - indexed for MEDLINE]
	Subsequent Detection of Clinically Significant Prostate Cancer After Suspicious MRI and an Initial Biopsy Negative for csPCa: A Longitudinal Subgroup Analysis of the MULTIPROS Trial. Prostate Aloufi WD, Szewczyk-Bieda M, Nabi G, Zhang X, Zhang Y, Wei C, Manfredi L. PMID: 42900782 [PubMed - as supplied by publisher]
	Spatial modulation enhances the effects of radiation on prostate cancer cells: a targeted mass spectrometry metabolomics study. Int J Radiat Biol Chen B, Rogers LJ, Liu K, Chen S, Deda R, Gotsbacher MP, Yang J, McKenzie DR, Suchowerska N, Kwan AH. PMID: 42900628 [PubMed - as supplied by publisher]
	Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open Gebrael G, Jo Y, Nandakumar V, Ozay ZI, Mercinelli C, Hooper G, Ostrowski M, Sayegh N, Lin E, Goel K, Li H, Thomas VM, Gupta S, Guha A, Riaz IB, Agarwal N, Swami U. PMID: 42900475 [PubMed - indexed for MEDLINE]
	Skin Toxic Effects and Survival With Enfortumab Vedotin-Pembrolizumab in Advanced Urothelial Carcinoma. JAMA Netw Open Thomas Z, Jiang CY, Speck PJ, Crupi E, Moussa MJ, Joseph A, Stender C, Glover M, Johns AC, Gao J, Desai M, Shah AY, Goswami S, Siefker-Radtke A, Karedath AR, Varughese SP, Ren W, Hassanzadeh C, Bree KK, Kamat AM, Guo CC, Pacha O, Patel A, Curry J, Sherry AD, Msaouel P, Campbell MT, Alhalabi O. PMID: 42900474 [PubMed - indexed for MEDLINE]
	Performance of(68)Ga-PSMA-11 PET/CT for Diagnosing Tumor Thrombus and Predicting Response to Pembrolizumab and Axitinib in Patients with Renal Cell Carcinoma: A Pilot, Retrospective Study. Ann Surg Oncol Lin BH, Zeng CL, Wu XH, Gao RC, Qiu QR, Chen YH, Xue XY, Zheng QS, Chen SH, Wei Y, Xu N. PMID: 42900428 [PubMed - as supplied by publisher]
	Nephrometry scores differ in their association with warm ischemia time during robot-assisted partial nephrectomy: comparison of RENAL, RPN, PADUA, and SPARE. J Robot Surg Komeya M, Kobayashi K, Jikuya R, Tatenuma T, Noguchi G, Ito H, Ito Y, Muraoka K, Hasumi H, Makiyama K. PMID: 42900398 [PubMed - indexed for MEDLINE]
	Bladder preservation is still feasible in the rare aggressive small cell carcinoma subtype. Med Oncol Ismail Y, Kamal A, Aboulkassem H, Ashour MG, AbouGabal AA, Allam RM, Gad M, Mostafa ME, Taher M. PMID: 42900317 [PubMed - indexed for MEDLINE]
	Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics. World J Urol Wenzel M, Le QC, Siech C, Hoeh B, Klimek K, Happel C, Saad F, Preisser F, Tilki D, Graefen M, Steuber T, Maurer T, Kriegmair MC, Karakiewicz PI, Chun FKH, Groener D, Mandel P. PMID: 42900232 [PubMed - indexed for MEDLINE]
	Vulnerability index impacts distribution of prostate cancer clinical trials in the United States. Front Oncol Abreu de Goes V, Mercier B, Jun Li Y, Shah K, Li X, Zhang G, Castro DV, Fann J, Jaime-Casas S, Lau LM, Lau LM, Lee J, Shah K, Swarat E, Dukkipati A, Agarwal R, Simon R, Goud J, Winayak R, Zugman M, Barragan-Carrillo R, Dizman N, Nguyen C, Pal SK, Chehrazi-Raffle A. PMID: 42899081 [PubMed]
	The Current Status and Evaluation of Artificial Intelligence in Bladder Cancer: Clinical Applications and Research. Comput Struct Biotechnol J Yin Z, Ho JWK. PMID: 42898717 [PubMed]
	Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up. J Bone Oncol de Albuquerque CFA, Reis LCS, Manna EDF, Zafalon AES, Yabrude ATZ, Porta C. PMID: 42898627 [PubMed]
	Bioengineering strategies to enhance BCG immunotherapy against bladder cancer. Front Immunol Li S, Chen H, Feng B. PMID: 42898624 [PubMed - indexed for MEDLINE]
	Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity. Pathol Oncol Res Alkan GV, Do, Türk Alkan M, Önder E. PMID: 42898355 [PubMed - indexed for MEDLINE]
	Impact of traditional Chinese medicine combined with conventional therapies on the survival of patients with metastatic prostate cancer: a retrospective observational cohort study. Front Oncol Zhou J, Yang S, Chen H, Hu L, Zhou Y, Jiang H, Mai J, Gan S, Chen Z, Xiang S. PMID: 42898136 [PubMed]
	Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Int J Urol Katayama S, Kawada T, Mori K, Iwatani K, Inoue S, Watanabe T, Tsuboi I, Yamanoi T, Iwata T, Tsuboi K, Murao W, Nakada T, Ogawa K, Matsukawa A, Yanagisawa T, Nishimura S, Bekku K, Wada K, Kimura T, Araki M. PMID: 42897807 [PubMed - indexed for MEDLINE]
	Medical students' knowledge, attitudes, and practices regarding renal pelvic cancer. BMC Med Educ Li Y, Feng Y, Hu S. PMID: 42897577 [PubMed - indexed for MEDLINE]
	Rare prostate cancer histologies: detection, characteristics and treatment. Nat Rev Urol Melão BVLA, Jardim DL, Li R, Collins K, Agarwal N, Grivas P, Briganti A, Necchi A, Cheng L, Spiess PE. PMID: 42897296 [PubMed - as supplied by publisher]
	Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. Cancer Med Tasaki Y, Sato K, Hamamoto S, Sugiyama Y, Ikoma H, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Tomita M, Mimura Y, Nagai T, Unno R, Etani T, Naiki T, Yasui T, Furukawa-Hibi Y. PMID: 42897107 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 182286

Page 1 of 9115



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy